grant
Project 1 - Longitudinal study of thrombotic thrombocytopenic purpura
Organization JOHNS HOPKINS UNIVERSITYLocation BALTIMORE, UNITED STATESPosted 15 Sept 2025Deadline 30 Jun 2030
NIHUS FederalResearch GrantFY20250-11 years old21+ years oldADAMTSAcuteAddressAdultAdult HumanAgeApoplexyBlood PlasmaBrain Vascular AccidentBrain Vascular DisordersBrain scanC2B8 Monoclonal AntibodyCerebral InfarctionCerebral IschemiaCerebral StrokeCerebrovascular ApoplexyCerebrovascular DiseaseCerebrovascular DisordersCerebrovascular StrokeChildChild YouthChildren (0-21)ChronicClinical DataClinical TrialsCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCollaborationsCountryDataDevelopmentDiagnosisDiseaseDisease remissionDisorderDisturbance in cognitionEnrollmentEvaluationExhibitsFoundationsFutureGoalsHealthHereditaryHypertensionImmuneImmunesImmunologic TestsImmunological TestsImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImpaired cognitionIncidenceInfrastructureInheritedInternationalInterventionIntervention TrialInterventional trialIntracranial Vascular DiseasesIntracranial Vascular DisordersLong-Term SurvivorsLong-term prospective studiesLongitudinal StudiesMR ImagingMR TomographyMRIMRI ScansMRIsMabTheraMagnetic Resonance ImagingMagnetic Resonance Imaging ScanMeasurementMeasuresMediatingMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMental disordersMental health disordersMorbidityMorbidity - disease rateMoschkowitz DiseaseMulti-center studiesMulticenter StudiesNMR ImagingNMR TomographyNatural HistoryNeurologicNeurologic DysfunctionsNeurologic EffectNeurologicalNuclear Magnetic Resonance ImagingOutcomeParticipantPathogenicityPatient Outcomes AssessmentsPatient RecruitmentsPatient Reported MeasuresPatient Reported OutcomesPatient advocacyPatientsPersonalized medical approachPhasePilot ProjectsPlasmaPlasma SerumPositionPositioning AttributePsychiatric DiseasePsychiatric DisorderQOLQuality of lifeRecombinantsRecurrenceRecurrentRegistriesRegulatory approvalRelapseRemissionReticuloendothelial System, Serum, PlasmaRisk FactorsRituxanStressStrokeSurvivorsThrombotic Thrombocytopenic PurpuraThrombotic Thrombopenic PurpuraUnited StatesVHHVHH antibodyVascular DiseasesVascular DisorderVascular Hypertensive DiseaseVascular Hypertensive DisorderWorkZeugmatographyadulthoodagesblood vessel disorderbrain MR imagingbrain MRIbrain attackbrain healthbrain magnetic resonance imagingbrain vascular diseasebrain vascular dysfunctioncamelid antibodycamelid based antibodycamelid derived antibodycamelid derived fragmentcamelid heavy chain only Abscamelid immunoglobulincamelid single chain antibodycamelid variable heavy chaincardiovascular disease riskcardiovascular disorder riskcerebral MR imagingcerebral MRIcerebral infarctcerebral magnetic resonance imagingcerebral vascular accidentcerebral vascular diseasecerebral vascular dysfunctioncerebrovascular accidentcerebrovascular dysfunctionclinical careclinical remissionco-morbidco-morbiditycognitive assessmentcognitive dysfunctioncognitive functioncognitive losscognitive testingcohortcomorbiditydevelopmentaldisease natural historyenrollhigh blood pressurehigh riskhyperpiesiahyperpiesishypertensive diseasehypertensive disorderimmune suppressionimmune suppressive activityimmune suppressive functionimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseindividualized approachindustrial partnershipindustry partnerindustry partnershipinnovateinnovationinnovativeintracranial vascular dysfunctionkidslong-term studylongitudinal outcome studieslongitudinal, prospective studymeetingmeetingsmental illnessmortalitynanobodiesnanobodyneurological dysfunctionnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyparticipant recruitmentpersonalized approachpilot studyprecision approachprevent relapseprospectivepsychiatric illnesspsychological disorderregulatory authorizationregulatory certificationregulatory clearancerelapse preventionrisk for strokerisk of strokerituximabsdAbsingle domain antibodiesstandard of carestroke riskstrokedstrokestailored approachthromboembolic complicationsthrombosis complicationsthrombotic complicationsvariable heavy chain antibodyvascular dysfunctionvasculopathyyoungster
Description preview
PROJECT SUMMARY – PROJECT 1
The overarching goal of this project is to develop the first multicenter, prospective, longitudinal study of
immune-mediated thrombotic thrombocytopenic purpura (iTTP) and the extremely rare congenital TTP (cTTP).
In survivors of both diseases, long-term complications include relapses, cognitive dysfunction, mental…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click